The more you understand about primary immunodeficiency (PI), the better you can live with the disease or support others in your life with PI. Learn more about PI, including the various diagnoses and treatment options.
Living with primary immunodeficiency (PI) can be challenging, but you’re not alone—many people with PI lead full and active lives. With the right support and resources, you can, too.
Be a hero for those with PI. Change lives by promoting primary immunodeficiency (PI) awareness and taking action in your community through advocacy, donating, volunteering, or fundraising.
Whether you’re a clinician, researcher, or an individual with primary immunodeficiency (PI), IDF has resources to help you advance the field. Get details on surveys, grants, and clinical trials.
Last night, Congress passed a massive piece of legislation to fund the government for the rest of the fiscal year and provide COVID-related funding and COVID relief to individuals and businesses. Included in this large package is a provision that would extend the Medicare In-Home IVIG Demonstration Project for another three years, to the end of 2023. Without this act of Congress, the demonstration was scheduled to expire at the end of this month. Now, patients on the IVIG In-Home Demonstration Project will be able to continue to receive their benefits for at least three more years.
The Immune Deficiency Foundation (IDF) applauds its bipartisan congressional champions, Rep. Doris Matsui (D-CA) and Rep. Kevin Brady (R-TX), for their dedication to including this important provision in the year-end legislation. This extension would not have been achieved without them, nor without the efforts of IDF and our passionate community advocates, who worked together to urge Congress to pass this vital piece of legislation.
Now that Congress has passed the bill, the President is expected to sign it into law before the year ends. Included in the legislation:
In addition to safeguarding in-home IVIG access for Medicare beneficiaries with PI, the end-of-year legislative package also includes language from the Preserving Patient Access to Home Infusions Act, ensuring that Medicare beneficiaries with PI will have continued access to all subcutaneous immunoglobulin (SCIG) products and services. The included section removes a barrier to coverage for Ig therapies designated as a self-administered drug (SAD) in local coverage determinations (LCD) by a Medicare Administrative Contractor.
Receive news and helpful resources to your cell phone or inbox. You can change or cancel your subscription at any time.
The Immune Deficiency Foundation improves the diagnosis, treatment, and quality of life for every person affected by primary immunodeficiency.
We foster a community that is connected, engaged, and empowered through advocacy, education, and research.
Combined Charity Campaign | CFC# 66309